GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Cyclically Adjusted PS Ratio

Sunho Biologics (HKSE:02898) Cyclically Adjusted PS Ratio : (As of May. 31, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Cyclically Adjusted PS Ratio?

Sunho Biologics does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sunho Biologics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sunho Biologics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Cyclically Adjusted PS Ratio Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
- - -

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Cyclically Adjusted PS Ratio - - - - -

Competitive Comparison of Sunho Biologics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sunho Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunho Biologics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunho Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sunho Biologics's Cyclically Adjusted PS Ratio falls into.


;
;

Sunho Biologics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sunho Biologics does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Sunho Biologics  (HKSE:02898) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sunho Biologics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunho Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Executives
Sunho Fortune Investments Limited 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Zhang Feng 2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited 2101 Beneficial owner

Sunho Biologics Headlines

No Headlines